SG10201907137RA - Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders - Google Patents
Use of an osmolyte in manufacture of a medicament for treatment of ocular disordersInfo
- Publication number
- SG10201907137RA SG10201907137RA SG10201907137RA SG10201907137RA SG10201907137RA SG 10201907137R A SG10201907137R A SG 10201907137RA SG 10201907137R A SG10201907137R A SG 10201907137RA SG 10201907137R A SG10201907137R A SG 10201907137RA SG 10201907137R A SG10201907137R A SG 10201907137RA
- Authority
- SG
- Singapore
- Prior art keywords
- osmolyte
- medicament
- manufacture
- treatment
- ocular disorders
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000000065 osmolyte Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201907137RA SG10201907137RA (en) | 2019-08-02 | 2019-08-02 | Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders |
| CN202311660101.7A CN117618414A (en) | 2019-08-02 | 2020-08-03 | Use of penetrant in preparation of medicament for treating ocular disorders |
| CN202080069185.5A CN114555075A (en) | 2019-08-02 | 2020-08-03 | Use of penetrants in the preparation of medicaments for treating eye disorders |
| PCT/SG2020/050447 WO2021025618A1 (en) | 2019-08-02 | 2020-08-03 | Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders |
| EP20849062.3A EP4007573A4 (en) | 2019-08-02 | 2020-08-03 | Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders |
| US17/632,240 US20220265591A1 (en) | 2019-08-02 | 2020-08-03 | Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201907137RA SG10201907137RA (en) | 2019-08-02 | 2019-08-02 | Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201907137RA true SG10201907137RA (en) | 2021-03-30 |
Family
ID=74504302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201907137RA SG10201907137RA (en) | 2019-08-02 | 2019-08-02 | Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220265591A1 (en) |
| EP (1) | EP4007573A4 (en) |
| CN (2) | CN117618414A (en) |
| SG (1) | SG10201907137RA (en) |
| WO (1) | WO2021025618A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013142912A1 (en) * | 2012-03-30 | 2013-10-03 | Brien Holden Vision Institute | Methods and compositions for reducing ocular discomfort |
| EA020401B1 (en) * | 2012-07-09 | 2014-10-30 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Pharmaceutical composition comprising sodium, calcium, magnesium, iron, zinc and having a metabolic, anti-cataract, retina-protecting effect (variants) |
| JP6769994B2 (en) * | 2015-04-28 | 2020-10-14 | スウェディッシュ オーファン バイオビトラム アクティエボラーグ （ペーウーベーエル） | Composition containing anakinra |
-
2019
- 2019-08-02 SG SG10201907137RA patent/SG10201907137RA/en unknown
-
2020
- 2020-08-03 CN CN202311660101.7A patent/CN117618414A/en active Pending
- 2020-08-03 EP EP20849062.3A patent/EP4007573A4/en active Pending
- 2020-08-03 CN CN202080069185.5A patent/CN114555075A/en active Pending
- 2020-08-03 US US17/632,240 patent/US20220265591A1/en active Pending
- 2020-08-03 WO PCT/SG2020/050447 patent/WO2021025618A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114555075A (en) | 2022-05-27 |
| EP4007573A4 (en) | 2023-08-23 |
| WO2021025618A1 (en) | 2021-02-11 |
| EP4007573A1 (en) | 2022-06-08 |
| CN117618414A (en) | 2024-03-01 |
| US20220265591A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276383B1 (en) | Treatment of ophthalmologic diseases | |
| IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
| IL273531A (en) | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases | |
| MX355770B (en) | Pharmaceutical composition of ibuprofen and tramadol for ophthalmological use. | |
| IL289405A (en) | Personalized treatment of ophthalmologic diseases | |
| IL287264A (en) | Compounds and methods for the treatment of ocular disorders | |
| IL284344A (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | |
| EP4058017A4 (en) | Drug formulations and methods of treatment for metabolic disorders | |
| IL269400A (en) | Drugs and compositions for the treatment of ocular disorders | |
| EP3675889A4 (en) | Angio-3 for treatment of retinal angiogenic diseases | |
| ZA202003944B (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| EP3919052A4 (en) | Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases | |
| SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
| SG10201907137RA (en) | Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders | |
| IL280588A (en) | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases | |
| PL3515409T3 (en) | Complex and compositions for the treatment of ophthalmic and dermatological diseases | |
| IL282898A (en) | Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases | |
| PT3897595T (en) | Nutraceutical ophthalmic composition for the treatment of retinal pathologies having a neovascular component | |
| MX2017012999A (en) | Pyrrolidone carboxylic acid (pca) for ophthalmic use. | |
| EP3976594A4 (en) | A therapeutic approach for treating non-infectious ocular immunoinflammatory disorders | |
| EP3939663A4 (en) | Therapeutic agent for corneal diseases | |
| NZ713490A (en) | Oral suspension for treating eosinophilic esophagitis | |
| EP4069220A4 (en) | Ophthalmic formulations for the treatment of presbyopia | |
| IL311706A (en) | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease | |
| AU2017904032A0 (en) | Implants for the Treatment of Diseases and Disorders |